Pharmaceutically effective compounds

1. A compound selected from:

i) a compound of formula I

wherein R 1 and R 2 are independently hydrogen, a straight chained C 1-6 alkyl group optionally substituted with a phenyl group, or a branched C 1-6 alkyl group optionally substituted with a phenyl group, or R 1 and R 2 together with the nitrogen atom attached thereto form a 5-7 membered saturated heterocyclic ring optionally containing further nitrogen and/or oxygen heteroatoms, wherein the heterocyclic ring is optionally substituted with one or more hydroxy, oxo or benzyl groups;

A is a phenyl group optionally substituted with one or more C 1-4 alkyl, C 1-4 haloalkyl, nitro group, or halogen, or is a 5-6 membered heteroaromatic ring containing at least one heteroatom selected from nitrogen, oxygen, and sulfur, wherein the nitrogen heteroatom is optionally a N-oxide structure;

n is 0, 1, or 2;

z is 0 or 1;

X is halogen or —NR 4 R 5 , wherein R 4 and R 5 are independently hydrogen, a straight chained C 1-6 alkyl group or a branched C 1-6 alkyl group,

Y is a hydrogen, hydroxy group, halogen, or C 1-22 acyloxy group, wherein if R 4 and R 5 are both hydrogen, then Y is other than a hydroxy group,

with the proviso that

a) if Y is hydrogen and/or X is an —NR 4 R 5 or if X is —NR 4 R 5 group,

R 1 and R 2 together with the nitrogen atom attached thereto form a 5-7 membered, saturated heterocyclic ring optionally containing further nitrogen and/or oxygen heteroatoms, wherein the heterocyclic ring is substituted with one or more hydroxy, oxo, or benzyl groups, and/or

A is a nitrogen-containing heteroaromatic ring, wherein said ring has a N-oxide structure on the nitrogen heteroatom, or

b) if X is halogen and Y is hydroxy or acyloxy, then

n is 1, or 2, and

R 1 and R 2 together with the nitrogen atom attached thereto form a 5-7 membered, saturated heterocyclic ring optionally containing further nitrogen and/or oxygen heteroatoms, wherein said heterocyclic ring is substituted with one or more hydroxy, oxo or benzyl groups, or a stereoisomer or salt thereof; and

ii) a compound of formula II

wherein R 1 and R 2 are independently hydrogen, a straight chained C 1-6 alkyl group optionally substituted with a phenyl group, a branched C 1-6 alkyl group optionally substituted with a phenyl group, or R 1 and R 2 together with the nitrogen atom attached thereto form a 5-7 membered saturated heterocyclic ring optionally containing further nitrogen and/or oxygen heteroatoms, wherein said heterocyclic ring is optionally substituted with one or more hydroxy, oxo or benzyl groups,

A is a phenyl group optionally substituted with one or more C 1-4 alkyl, C 1-4 haloalkyl, nitro, or halogen, or is a 5-6 membered heteroaromatic ring containing at least one heteroatom selected from nitrogen, oxygen, and sulfur, wherein the nitrogen heteroatom is optionally a N-oxide structure;

n 0, 1, or 2;

z is 0 or 1;

X is oxygen;

R 3 is selected from hydrogen, straight chained C 1-6 alkyl group, and branched chained C 1-6 alkyl group;

Y is selected from hydrogen, hydroxy, halogen, and C 1-22 acyloxy group,

with the proviso that if Y is other than halogen, then

n is 1, or 2, and

R 1 and R 2 together with the nitrogen atom attached thereto form a 5-7 membered, saturated heterocyclic ring optionally containing further nitrogen and/or oxygen heteroatoms, wherein said heterocyclic ring is substituted with one or more hydroxy, oxo or benzyl groups and/or

A is a nitrogen-containing heteroaromatic ring, which has a N-oxide structure on the nitrogen heteroatom;

or a stereoisomer or salt thereof.

2. The compound according to claim 1 , wherein the compound is N-[2-hydroxy-3-(1-piperidinyl)propoxy]-pyridin-1-oxide-3 carboxamide, or a stereoisomer or salt thereof.

3. A pharmaceutical composition comprising a compound according to claim 1 and a pharmaceutically acceptable carrier.

4. The compound according to claim 1 , wherein the compound is a compound of formula I as defined in claim 1 .

5. The compound according to claim 4 , wherein

R 1 and R 2 together with the nitrogen atom attached thereto form piperidinyl or morpholino ring optionally substituted with one or more hydroxy, oxo, or benzyl groups,

A is a phenyl group optionally substituted with one or more nitro group, or a pyridinyl group optionally substituted with one or more C 1-4 alkyl group, wherein the nitrogen of the pyridinyl group is optionally a N-oxide structure,

z=0 or 1,

X is halogen or —NR 4 R 5 , wherein R 4 and R 5 are independently hydrogen, a straight chained C 1-6 alkyl group or a branched C 1-6 alkyl group,

Y is a hydrogen, hydroxy group, or halogen;

or a stereoisomer or salt thereof.

6. The compound according to claim 5 , wherein the compound is N-[3-(1-piperidinyl)propoxy]-pyridin-1-oxide-3-carboxamidine or a salt thereof.

7. The compound according to claim 5 , wherein the compound is N-[3-(1-piperidinyl)propoxy]-pyridin-1-oxide-3-carboximidoyl chloride.

8. The compound according to claim 5 , wherein the compound is N-[2-hydroxy-3-(1-piperidinyl)propoxy]-N′-n-butyl-pyridin-1-oxide-4-carboxamidine, or a stereoisomer or salt thereof.

9. The compound according to claim 5 , wherein the compound is N-[3-(1-oxido-1-piperidinyl)propoxy]-3-nitro-benzimidoyl chloride, or a hydrate and/or salt thereof.

10. The compound according to claim 5 , wherein the compound is 2-chloro-N-[3-(4-oxido-4-morpholinyl)propoxy]-benzimidoyl chloride or a salt thereof.

11. The compound according to claim 5 , wherein the compound is N-[2-chloro-3-(1-piperidinyl)propoxy]benzimidoyl chloride hydrochloride, or a stereoisomer or salt thereof.